Pilot shows promise for pharmacist role in improving blood pressure outcomes
BLOOMINGTON, Minn. — Results from a community partnership between HealthPartners, Sterling pharmacy, and PharmaSmart show the potential of community pharmacists to improve hypertension. Nearly one in three American adults are estimated to have high blood pressure, which can cause heart failure, heart attack, stroke, and kidney damage.
The six-month pilot program included 270 HealthPartners members who had a diagnosis of hypertension and a prescription for medication to lower blood pressure at a Sterling pharmacy. Members who enrolled received a Smart Card which allowed them to routinely measure and track their blood pressure on a PharmaSmart blood pressure kiosk inside the Sterling stores. The clinically validated PharmaSmart kiosks contain technology to automatically transmit the data into the Sterling pharmacy clinical system. This unique integration allows pharmacists to proactively intervene on the patient’s behalf by recommending a change in dose or a new medication to the patient’s provider.
“One of the key findings of the pilot program is the importance of personal interaction between the patient and the pharmacist,” said Tim Gallagher, President of Astrup Drug, Inc. which owns and operates Sterling pharmacies. “Pharmacists have the opportunity to extend the care team and optimize therapy to positively impact patient outcomes.”
Half of participants had uncontrolled blood pressure
Nearly half of the active members in the pilot program had uncontrolled blood pressure despite the fact that they had a prescription for medication to control it. Sterling pharmacists were able to recommend a change in dose or medication to the patient’s provider. As a result, blood pressure improved for about one third of patients through the course of the pilot, with a mean reduction in blood pressure among the uncontrolled group of -11 mmHg systolic and -8 mmHg diastolic.
The pilot program was implemented after a HealthPartners analysis revealed a similar gap between medication adherence and appropriate clinical outcomes. The analysis found that about 85 percent of patients with a diagnosis of hypertension had filled their prescriptions in a timely manner. However, a comparison of pharmacy claims with medical records revealed that for about one third of patients, the medication was not having the desired effect and patients still had uncontrolled blood pressure.
“It is well understood that the pharmacist can play a key role in supporting medication adherence. This pilot shows that community pharmacists can add even more value by confirming that the prescribed medication is doing what it is supposed to do,” said Richard Bruzek, vice president of HealthPartners pharmacy services. Based on the promising results of the pilot program, HealthPartners is exploring program expansion in 2016.
I'm very interested in the findings presented in this article. Is there a reference and/or have the results been published in a peer-reviewed journal somewhere? I'd appreciate any additional information on how to track down the details. Thanks!
Walgreens, UN Foundation expand ‘Give a Shot’ offering for #GivingTuesday
No comments found
Diplomat to dispense Takeda’s Ninlaro
FLINT, Mich. — Diplomat Pharmacy announced last week that it would be among the network of specialty pharmacies dispensing Takeda’s Ninlaro, a treatment for patients with multiple myeloma who have had prior therapy.
The oral proteasome inhibitor works by blocking proteasomes, which are enzymes that help break down old or unwanted proteins. Blocking them makes a cancer cell’s survival more difficult by disrupting protein metabolism.
“We are excited to offer patients the first oral proteasome inhibitor as an alternative treatment option for those with multiple myeloma,” Diplomat president Gary Kadlec said. “This breakthrough therapy will serve as an important treatment option for patients with unmet needs.”
No comments found